The GLP is committed to full transparency. Download and review our 2019 Annual Report

Questionable genetic test marketing comes at expense of patients’ health and safety

| | February 12, 2016
This article or excerpt is included in the GLP’s daily curated selection of ideologically diverse news, opinion and analysis of biotechnology innovation.

The GLP aggregated and excerpted this blog/article to reflect the diversity of news, opinion and analysis.

An average of eight to 10 genetic testing products are being put on the market every day, according to a recent estimate. But in the rush to put tests in physicians’ hands, our investigation found profit being placed above scientific proof, reports CBS News correspondent Jim Axelrod.

The explosion of unproven lab-developed tests on the market is a big concern for researchers like Dr. Theodora Ross, who runs the cancer genetics program at the University of Texas Southwestern.

“I think that people are not waiting long enough before they send the test out,” Ross said.

She agreed the science gets shortchanged in the face of business.

“If the FDA were to come in and say, ‘Show me your data,’ they couldn’t show the data, they should not be testing these patients,” Ross said.

Read full, original post: In modernday gold rush of genetic testing, profit placed above proof

Share via
News on human & agricultural genetics and biotechnology delivered to your inbox.
Optional. Mail on special occasions.
Send this to a friend